- Hematology in Clinical Practice
- Search Author Details
Author Details
Sacha, Tomasz
-
Vol 2, No 3 (2011) - REVIEW ARTICLE
First-line chronic myeloid leukemia treatment with 2nd generation tyrosine kinase inhibitors; a path to cure?
Abstract PDF (Polish) -
Vol 1, No 3 (2010) - REVIEW ARTICLE
The use of tyrosine kinase inhibitors in the second line treatment of patients with chronic myeloid leukemia
Abstract PDF (Polish) -
Vol 2, Supp. B (2011) - REVIEW ARTICLE
The history of treatment of chronic myeloid leukemia
Abstract PDF (Polish) -
Vol 2, Supp. B (2011) - CASE REPORT
Major molecular response achieved after nilotinib therapy in the patient suffering from chronic myeloid leukemia with hematologic toxicity associated with imatinib and dasatinib therapy
Abstract PDF (Polish) -
Vol 2, Supp. B (2011) - CASE REPORT
Successful nilotinib therapy in the patient with suboptimal response of chronic myeloid leukemia to imatinib treatment associated with non-hematological toxicity
Abstract PDF (Polish) -
Vol 3, No 1 (2012) - REVIEW ARTICLE
Advances in the therapy of primary myelofibrosis
Abstract PDF (Polish) -
Vol 3, No 3 (2012) - CASE REPORT
Successful therapy with dasatinib in patient with recurrent liver toxicity associated with imatinib and nilotinib administration
Abstract PDF (Polish) -
Vol 4, No 1 (2013) - REVIEW ARTICLE
Is it possible to improve the results of fi rst line therapy for chronic myeloid leukemia in chronic phase?
Abstract PDF (Polish) -
Vol 4, Supp. B (2013) - CASE REPORT
Major molecular response achieved on the third-line nilotinib therapy in a patient with chronic myelogenous leukemia in chronic phase with suboptimal response to imatinib and dasatinib
Abstract PDF (Polish) -
Vol 4, Supp. B (2013) - CASE REPORT
Complete molecular response achieved on the third-line nilotinib therapy in a patient with chronic myelogenous leukemia in chronic phase intolerant to imatinib and dasatinib
Abstract PDF (Polish) -
Vol 4, No 3 (2013) - REVIEW ARTICLE
Effi cacy of primary myelofi brosis therapy with JAK2 inhibitors
Abstract PDF (Polish) HTML (Polish) -
Vol 5, No 1 (2014) - REVIEW ARTICLE
Comparing the efficacy of nilotinib and imatinib in the first line treatment of chronic myelogenous leukaemia during its chronic phase and their effects on long term outcomes…
Abstract PDF (Polish) HTML (Polish) -
Vol 5, No 2 (2014) - REVIEW ARTICLE
Quality of life of patients suffering from primary myelofibrosis is important parameter in assessment of treatment efficacy
Abstract PDF (Polish) HTML (Polish) -
Vol 5, No 2 (2014) - REVIEW ARTICLE
Co-morbidities in patients suffering from chronic myelogenous leukemia and tyrosine kinase inhibitor choice
Abstract PDF (Polish) HTML (Polish) -
Vol 6, No 1 (2015) - REVIEW ARTICLE
Advances in therapy of patients with chronic myelogenous leukemia
Abstract PDF (Polish) HTML (Polish) -
Vol 8, Supp. B (2017) - CASE REPORT
Komentarz
Details PDF (Polish) -
Vol 8, Supp. B (2017) - CASE REPORT
Komentarz
Details PDF (Polish) -
Vol 10, No 3 (2019) - EXPERTS' POSITION
Advanced systemic mastocytosis — experts’ statement on diagnostic and therapeutic approach
Abstract PDF (Polish) -
Vol 12, Supp. A (2021) - CASE REPORT
Wydłużenie przeżycia u chorej na przewlekłą białaczkę szpikową w fazie kryzy blastycznej leczonej ponatynibem
Abstract PDF (Polish) -
Vol 12, Supp. A (2021) - CASE REPORT
Nadciśnienie tętnicze i inne działania niepożądane terapii ponatynibem w układzie sercowo-naczyniowym u 60-letniego chorego na przewlekłą białaczkę szpikową
Abstract PDF (Polish)
Important: This website uses cookies. More >>
The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.
By VM Media Group sp. z o.o., Grupa Via Medica, ul. Świętokrzyska 73, 80–180 Gdańsk, Poland
phone:+48 58 320 94 94, fax:+48 58 320 94 60, e-mail: viamedica@viamedica.pl